• Najat Bouchkouj, Yvette L Kasamon, R Angelo de Claro, Bindu George, Xue Lin, Shiowjen Lee, Gideon M Blumenthal, Wilson Bryan, Amy E McKee, and Richard Pazdur.
• Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland. najat.bouchkouj@fda.hhs.gov.
• Clin Cancer Res. 2019 Mar 15; 25 (6): 1702-1708.

AbstractIn October 2017, the FDA granted regular approval to axicabtagene ciloleucel, a CD19-directed chimeric antigen receptor (CAR) T-cell therapy, for treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Efficacy was based on complete remission (CR) rate and duration of response (DOR) in 101 adult patients with relapsed or refractory large B-cell lymphoma (median 3 prior systemic regimens) treated on a single-arm trial. Patients received a single infusion of axicabtagene ciloleucel, preceded by lymphodepleting chemotherapy with cyclophosphamide and fludarabine. The objective response rate per independent review committee was 72% [95% confidence interval (CI), 62-81], with a CR rate of 51% (95% CI, 41-62). With a median follow-up of 7.9 months, the median DOR was not reached in patients achieving CR (95% CI, 8.1 months; not estimable, NE), whereas patients with partial remission had an estimated median DOR of 2.1 months (95% CI, 1.3-5.3). Among 108 patients evaluated for safety, serious adverse reactions occurred in 52%. Cytokine release syndrome and neurologic toxicities occurred in 94% and 87% of patients, respectively, leading to implementation of a risk evaluation and mitigation strategy.©2018 American Association for Cancer Research.

50 keywords...

hide…